Repatha 'actual net prices' bring value for money, says analysis

US biotech major Amgen (Nasdaq: AMGN) has pointed to new analysis suggesting that the US price of its cholesterol lowerer Repatha (evolocumab) does not need to be cut by more than two thirds to meet generally accepted cost-effectiveness thresholds.

Earlier studies have suggested that Amgen’s $14,523 list price is far too high, including one published in the Journal of the American Medical Association (JAMA) that claimed that the price of the PCSK9 drug would need to be reduced by around 71%, to around $4,536, to meet generally accepted cost-effectiveness thresholds.

"The analysis identifies the types of high-risk patients for whom this therapy is both clinically beneficial and cost-effective"